Seizert Capital Partners LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 256,947 shares of the company’s stock after selling 5,590 shares during the period. Johnson & Johnson makes up about 2.4% of Seizert Capital Partners LLC’s holdings, making the stock its 7th largest position. most recent SEC filing.

→ The Next Big Crisis Is Here (From Porter & Company)

Several other large investors have also added to or reduced their stakes in JNJ. Morton Brown Family Wealth LLC boosted its holdings in Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s worth200th $3 stock After acquiring an additional 78 shares in the last quarter. Goodman Advisory Group LLC bought a new position in shares of Johnson & Johnson in the second quarter valued at approximately $39,000. First Bank & Trust lifted its holdings in shares of Johnson & Johnson9.6% by 6% in the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after purchasing an additional 156 shares in the last quarter. Heritage Wealth Management LLC bought a new position in shares of Johnson & Johnson in the art value second qu at approximately $84,000. Finally, Timber Creek Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 225.0% in the third quarter. Timber Creek Capit al Management LLC now owns 650 shares of the company’s stock valued at $106,000 after purchasing an additional 450 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on JNJ shares. Citigroup increased their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Sanford C. Bernstein reduced their price target on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Morgan Stanley lifted their price objective on Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research note on Wednesday. Raymond James dropped their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, October 19th. Finally, Credit Suisse Group initiated coverage on Johnson & Johnson in a research note on Thursday , November 17th. They set a “neutral” rating and a $170.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $182.75.

Insider Transactions at Johnson & Johnson

In related news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following, the ice transaction The president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CFO Joseph J. Wolk sold 14,781 shares of John stockson & John in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares in valued 3 at the 2 company, 6 . The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now owns 40,133 shares of the company’s stock, discounted at $6,869, a sale. The for 6 can be found here. Over the last three months, insiders have sold 233,611 shares of company stock valued at $40,960,735. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Down 0.4%

Shares of JNJ stock opened at $168.89 on Friday. The firm has a market capitalization of $441.56 billion, a PE ratio of 25.06, a PEG ratio of 3.00 and a beta of 0.56. The stock has a fifty day simple moving average of $175.90 and a two-hundred day simple moving average of $171.04. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a 52-week low of $155.72 and a 52- week high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin 18.90% and a return on equity of 35.94%. The firm had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same quarter last year, the firm earned $2.13 EPS. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 10.55 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend of 2.68%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or out comments about this story [email protected].

Before you consider Johnson & Johnson, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before market the broader on… and Johnson & Johnson wasn’t on the list.

While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here